Merck & Company Inc (MRK)vsVanda Pharmaceuticals Inc (VNDA)
MRK
Merck & Company Inc
$146.99
-0.16%
HEALTHCARE · Cap: $368.89B
VNDA
Vanda Pharmaceuticals Inc
$3.95
-4.82%
HEALTHCARE · Cap: $230.99M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 29287% more annual revenue ($67.38B vs $229.28M). MRK leads profitability with a 3.6% profit margin vs -119.9%. VNDA appears more attractively valued with a PEG of 2.23. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
VNDA
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.99
$62.12 premium
Margin of Safety
+83.7%
Fair Value
$37.45
Current Price
$3.95
$33.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 24.1% year-over-year
Areas to Watch
Trading at 8.7x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -60.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : VNDA
The strongest argument for VNDA centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 24.1% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : VNDA
The primary concerns for VNDA are PEG Ratio, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while VNDA is a growth play — different risk/reward profiles.
VNDA carries more volatility with a beta of 0.73 — expect wider price swings.
VNDA is growing revenue faster at 24.1% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 42/100). VNDA offers better value entry with a 83.7% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Vanda Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?